# Innovent Announces Phase 3 CREDIT-5 Study Met Primary Endpoint, SINTBILO® (Tafolecimab Injection) as First-line Monotherapy Treatment for Hyperlipidemia Demonstrated Potent Lipid-lowering Efficacy

- Source: PR Newswire M&A
- Published: 2026-11-09T00:00:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/innovent-announces-phase-3-credit-5-study-met-primary-endpoint-sintbilo-tafolecimab-injection-as-first-line-monotherapy-treatment-for-hyperlipidemia-demonstrated-potent-lipid-lowering-efficacy-302932681.html
- Canonical: https://groundlevelnews.com/story/innovent-announces-phase-3-credit-5-study-met-primary-endpoint-sintbil-eb2db7/

SINTBILO® (tafolecimab injection) monotherapy achieved significant reduction of LDL-C level, with > 60% mean LDL-C reduction after 12 weeks of treatment with 150 mg Q2W/450 mg Q4W SINTBILO® (tafolecimab injection) monotherapy significantly decreased non-HDL-C, vLDL-C, ApoB, and Lp(a)...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._